News NICE must be reformed - Janssen UK market access chief Janssen’s UK pricing chief Jennifer Lee has called for reform of NICE following the company’s successful but drawn-out attempt to get its cancer drug Darzalex to NHS patients.
News Roche's MS drug Ocrevus priced in line with Novartis rival i... Drug likely to cost just under £10,000 per six-monthly injection.
News Pharma collaborates to improve chances of NICE backing Duche... Project will initially focus on DMD but could benefit other rare diseases
News Spark divides opinion with $850,000 gene therapy Spark offers efficacy-based rebates and deferred payments to mitigate costs
News NHS should fund GSK's £526,000 "bubble baby" drug - NICE Strimvelis is most expensive drug cleared by NICE
News NICE to reassess Pfizer blood cancer drug Company successfully appealed against rejection last summer
News Gilead strikes again, penning $5bn deal to buy Tubulis Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.